VEGF and TGF-β1 induce angiogenesis but have opposing effects on endothelial cells.
INTRODUCTION
Angiogenesis, the formation of capillaries from preexisting blood vessels, occurs in a variety of physiological and pathological settings, including embryonic development, wound healing and tumor growth. A number of cytokines and growth factors modulate angiogenesis. Among them, vascular endothelial growth factor (VEGF) and transforming growth factor-beta 1 (TGF-β1) play prominent roles (Ferrara, 2004; Massague et al., 2000; Presta et al., 2005) . VEGF controls a variety of endothelial cell functions involved in angiogenesis and protects endothelial cells from apoptosis (Hicklin and Ellis, 2005) . VEGF transcription can be modulated by multiple stimuli (Levy et al., 1995; Liu et al., 1995; Tischer et al., 1991) , among which hypoxia plays a major role (Forsythe et al., 1996; Liu et al., 1995; Shweiki et al., 1992) . In addition, cytokines and growth factors upregulate VEGF expression in a variety of cell types (Goldman et al., 1993; Li et al., 1995; Pertovaara et al., 1994) . Fibroblast growth factor-2 (FGF-2) and TGF-β1 induce VEGF expression in vascular endothelial cells (Ferrari et al., 2006; Seghezzi et al., 1998) . VEGF activates two tyrosine kinase receptors, flt-1 (VEGFR-1) and flk-1 (VEGFR-2) (Hicklin and Ellis, 2005) . Flk-1 has been implicated in endothelial cell proliferation and survival, and flt-1 in chemotaxis and vascular permeability (Gille et al., 2001; Keyt et al., 1996) . VEGF, flk-1, and flt-1 are indispensable for angiogenesis and their genetic deficiency causes embryonic lethality as a result of blood vessels disorganization, endothelial cell overgrowth or impaired endothelial cell development (Carmeliet et al., 1996; Ferrara et al., 1996) . In tumors VEGF expression correlates with tumor vascularity and progression. Inhibition of VEGF results in decreased tumor vascularity and growth, implicating VEGF as the major tumor angiogenesis factor (Ferrara, 2004) . Pharmacological treatments targeting VEGF or VEGFR-2 are currently used or in advanced clinical trials for the therapy of several malignancies (Ferrara, 2004; Ferrara and Kerbel, 2005) .
TGF-β1 is an important regulator of tissue morphogenesis and a potent inhibitor of proliferation for most cell types (Massague et al., 2000) . Half of mice genetically deficient in TGF-β1 die in utero and show defective vasculogenesis, a phenotype consistent with abundant TGF-β1 gene expression in endothelial precursors (Dickson et al., 1995) . TGF-β1 has multiple effects on vascular endothelial cells. In vivo TGF-β1 induces angiogenesis (Madri et al., 1988; Roberts et al., 1986; Yang and Moses, 1990 ). However, in vitro it inhibits endothelial cell proliferation (Pollman et al., 1999b) , migration and proteolytic activity, opposes the stimulatory effect of FGF-2 on these endothelial cell functions (Pepper et al., 1990; Saksela et al., 1987) , and downregulates flk-1 expression (Mandriota et al., 1996) . Notably, TGF-β1 induces endothelial cell apoptosis, opposing the prosurvival activity of VEGF (Pollman et al., 1999a; b) . (Choi and Ballermann, 1995) , indicating that the apoptotic effect of TGF-β1 on endothelial cells is an important component of its angiogenic activity.
Inhibition of apoptosis abrogates TGF-β1-induced angiogenesis in vitro
During angiogenesis apoptosis is required for pruning the forming vascular network, and inhibition of apoptosis results in formation of abnormal vessels (Pollman et al., 1999a) . In addition, apoptosis controls cell functions required for capillary morphogenesis in vitro and in vivo (Choi and Ballermann, 1995; Segura et al., 2002) . Because of its inhibitory effects on endothelial cells it has been proposed that TGF-β1 induces angiogenesis in vivo through an indirect mechanism, by inducing expression of VEGF and/or other angiogenic factors in epithelial or other cell types (Pardali and Moustakas, 2007) .
VEGF and TGF-β1 are often co-expressed in tissues in which angiogenesis occurs, notably in a variety of tumors (Pardali and Moustakas, 2007) .
However, although numerous studies have investigated the mechanisms through which these individual growth factors control angiogenesis, their interactions at the level of endothelial cells are poorly understood. We have recently shown that TGF-β1 upregulates endothelial cell expression of VEGF, and that TGF-β1 induction of endothelial cell apoptosis is mediated by activation of flk-1 by VEGF (Ferrari et al., 2006) . This finding raised an important question: Does this mechanism inhibit or stimulate blood vessel formation by TGF-β1? Here we report that VEGF-mediated apoptosis is required for TGF-β1 induction of angiogenesis in vitro and in vivo.
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RESULTS
Endothelial cell-derived VEGF controls TGF-β1 induction of in vitro angiogenesis
TGF-β1 induces vascular endothelial cell expression of VEGF, which mediates the apoptotic activity of TGF-β1 through activation of flk-1 (Ferrari et al., 2006) . Because TGF-β1 induces angiogenesis in vitro and in vivo (Choi and Ballermann, 1995; Segura et al., 2002; Yang and Moses, 1990) , we hypothesized that endothelial cell VEGF also controls the angiogenic activity of TGF-β1. To test this hypothesis, confluent BCE cells grown on gelatin-coated dishes were incubated in the presence or absence of TGF-β1, and TGF-β1 was added to the medium every 24 h. Under these experimental conditions TGF-β1 induced apoptosis within 6 h to 12 h of incubation. Subsequently apoptosis decreased to control levels and further addition of TGF-β1 to the culture medium did not induce cell death (Fig. 1 A) . In the absence of TGF-β1 the cells grew as a compact monolayer (Fig. 2 A, panel a) . Addition of TGF-β1 to the culture medium induced formation of lumen-containing capillary-like structures (in vitro angiogenesis) within 72 h to 120 h (panel b), as described (Choi and Ballermann, 1995) .
We then characterized the effect of neutralizing anti-VEGF and anti-FGF-2 antibodies on TGF-β1 induction of in vitro angiogenesis. VEGF antibody blocks the apoptotic activity of TGF-β1 on endothelial cells, whereas antibody to FGF-2 induces apoptosis in the presence or absence of TGF-β1 (Ferrari et al., 2006) . Both antibodies blocked TGF-β1 induction of angiogenesis but with different effects. In the presence of VEGF antibody TGF-β1-treated cells (panel n) retained an intact monolayer. In contrast, addition of FGF-2 antibody to TGF-β1-treated cells caused massive cell death, with 6 sparse, disrupted capillary-like structures (panel k). This effect can be explained by our previous findings that anti-FGF-2 antibody induces endothelial cell apoptosis, and that FGF-2 -/-endothelial cells have higher apoptosis levels than wt cells (Ferrari et al., 2006) .
To analyze the role of apoptosis in TGF-β1 induction of in vitro angiogenesis we used z-VAD, a general caspase inhibitor that blocks apoptosis. z-VAD blocked induction of in vitro angiogenesis by TGF-β1 ( (Fig. 3 A) . Downregulation of flk-1 expression blocks TGF-β1 induction of endothelial cell apoptosis, whereas inhibition of flt-1 expression has no such effect (Ferrari et al., 2006) . Flk-1 siRNA-transfected cells did not undergo apoptosis although they were treated with TGF-β1 every 24 h for up to 72 h (Fig. 3 B) ,
showing that downregulation of flk-1 expression did not provide an apoptotic stimulus per se. However, transfection with flk-1 siRNA abrogated both the apoptotic effect of TGF-β1 (Fig. 3 B) and TGF-β1 induction of in vitro angiogenesis ( Fig. 3 C and D) . In contrast downregulation of flt-1 expression, which does not affect TGF-β1 induction of apoptosis (Ferrari et al., 2006) , had no effect on in vitro angiogenesis ( Fig. 3 C and D) .
The inhibitory effect of z-VAD and of antibodies to FGF-2 or VEGF on in vitro angiogenesis was rapidly reverted after removal of these reagents from the culture medium ( Fig. 2, (Bautch et al., 2000; Bautch et al., 1996; Desbaillets et al., 2000; Feraud et al., 2001; Gualandris et al., 2000b; Mallet et al., 2006; Ng et al., 2004) .
Consistent with previous reports (Gualandris et al., 2000b; Vittet et al., 1996) , wt embryoid bodies formed vascular structures that were increased by exogenous 8 VEGF; conversely, in the presence of exogenous TGF-β1 the endothelial cells formed thick cords (Fig. 4) . In VEGF-deficient embryoid bodies endothelial cells were dramatically reduced in number and formed no vessel-like structures. Addition of exogenous VEGF to these cells restored the wt phenotype almost completely. In contrast, treatment with TGF-β1 had no such effect. Embryoid bodies from ES cells deficient in flt-1 showed a vascular phenotype comparable to that of wt embryoid bodies, and responded both to exogenous VEGF and TGF-β1 in a manner similar to wt embryoid bodies. Conversely, flk-1 KO embryoid bodies showed few endothelial cells that were sparse or formed occasional clusters but no vascular structures, and this phenotype was not corrected by addition of either VEGF or TGF-β1 (Fig. 4) . Therefore, consistent with our results obtained by siRNA-mediated downregulation of VEGF receptors in mature endothelial cells (Fig. 4) , these results indicated that the effect of TGF-β1 on embryoid body generation of vascular structures is mediated by VEGF.
To confirm and quantitate this finding we analyzed ICAM-2 expression by RT-PCR and real-time PCR (Fig. 5) . The results were similar to those obtained by studying ICAM-2 protein expression by immunofluorescence analysis. At day 9 of differentiation, when endothelial cell differentiation is complete (Balconi et al., 2000; Vittet et al., 1996) , ICAM-2 mRNA expression was reduced 9.1-, 15.9-and 5.3-fold in VEGF-, flk-1-and flt-1-deficient embryoid bodies, respectively, relative to wt embryoid bodies. Both VEGF and TGF-β1 induced a nearly twofold increase of ICAM-2 mRNA levels in wt embryoid bodies. VEGF also increased ICAM-2 levels in VEGF KO embryoid bodies up to wt level. In contrast, TGF-β1 had no such effect, showing that the action of TGF-β1 on ICAM-2 expression is dependent on VEGF signaling. Addition of VEGF or TGF-β1 had no significant effect on ICAM-2 mRNA levels in flt-1 KO and flk-1 KO embryoid bodies.
Thus, these results showed that TGF-β1 induction of endothelial cell differentiation (vasculogenesis) and angiogenesis requires VEGF signaling.
VEGF mediates the apoptotic activity of TGF-β1 in vivo
To assess the biological significance of our findings in vivo we tested the effect of neutralizing antibody to VEGF on TGF-β1 induction of endothelial cell apoptosis in the chicken embryo choriollantoic membrane (CAM). For this purpose we treated chicken embryo CAMs with TGF-β1 in the absence or presence of neutralizing VEGF antibody. We used a TGF-β1 concentration that induces angiogenesis in the CAM (Yang and Moses, 1990) . After 6 h incubation we analyzed CAM sections by TUNEL and immunostaining with antibody to CD31, an endothelial cell marker. Analysis of the sections by confocal microscopy ( Fig. 6 ) showed that TGF-β1 strongly upregulated the number of TUNEL-positive (apoptotic) cells in the CAM with an effect comparable to that of TNF-α, a potent inducer of endothelial cell apoptosis (Ferrari et al., 2006) .
Virtually all apoptotic cells colocalized with CD31-positive (endothelial) cells, consistent with previous reports that TGF-β1 selectively induces apoptosis in endothelial cells but not in smooth muscle cells or pericytes (Pollman et al., 1999b) . VEGF antibody strongly downregulated the number of TUNEL-positive cells induced by TGF-β1, whereas control n.i. IgG had no such effect (Fig. 6 ). Thus, these results showed that TGF-β1 induction of endothelial cell apoptosis in vivo requires VEGF signaling.
VEGF mediates TGF-β1 induction of angiogenesis in vivo
We then tested the effect of neutralizing anti-VEGF antibody on TGF-β1
induction of blood vessel formation in the CAM. As described (Yang and Moses, 1990), TGF-β1 induced formation of new capillaries from pre-existing CAM vessels with an effect comparable to that of FGF-2. The vessels formed in the presence of TGF-β1 were relatively large and had few branches, whereas those induced by FGF-2 were thin and had many branches ( Fig. 7 A and B) (Yang and Moses, 1990) . To confirm that our VEGF antibody neutralized chicken VEGF, we tested if it blocked angiogenesis induction in the CAM by FGF-2. We have previously shown that FGF-2 upregulates endothelial cell expression of VEGF, and that antibody to VEGF blocks FGF-2 induction of angiogenesis in vivo (Seghezzi et al., 1998) . VEGF antibody blocked the angiogenic effect of FGF-2 in the CAM, showing that it neutralized chicken VEGF ( Fig. 7 A and B) . We therefore tested the effect of VEGF antibody on TGF-β1 induction of angiogenesis. TGF-β1 increased the number of CAM vessels approximately 2.5-fold, an effect comparable to that obtained with FGF-2 and consistent with previous findings (Yang and Moses, 1990 ).
Antibody to VEGF completely abrogated this effect, showing that TGF-β1 induces angiogenesis in vivo through the autocrine and/or paracrine action of VEGF.
Because VEGF mediates the apoptotic activity of TGF-β1 on the CAM endothelial cells, these results indicated that the rapid apoptotic effect mediated by VEGF is required for TGF-β1 induction of angiogenesis in vivo. Therefore, we treated CAMs with TGF-β1 in the presence or absence of z-VAD, a general caspase inhibitor that blocks in vitro angiogenesis (Fig. 2, panel q) . As shown in Figure 7 C and D, z-VAD completely abrogated the angiogenic activity of TGF-β1 with an effect comparable to that of VEGF antibody. Thus, these results showed that rapid and transient upregulation of VEGF-flk-1-mediated endothelial cell apoptosis is required for TGF-β1 induction of angiogenesis in vivo.
12
DISCUSSION
We have previously shown that the rapid induction of endothelial cell apoptosis by TGF-β1 is mediated by the autocrine or paracrine activation of VEGF receptor 2 (flk-1) by endothelial cell VEGF (Ferrari et al., 2006) . However, a fundamental question remained to be answered: Does VEGF-mediated apoptosis promote or inhibit TGF-β1-induced angiogenesis? The data reported here show that that VEGFmediated apoptosis is an early event required for induction of blood vessel formation by TGF-β1. Therefore, endothelial cell apoptosis is not only necessary for pruning the forming vascular network during the late stages of angiogenesis; it also occurs in the initial steps of, and is required for angiogenesis to proceed.
Our finding that TGF-β1-induced endothelial cell apoptosis is transient and followed by a long period in which the cells are refractory to the apoptotic effect of TGF-β1 can be explained by two non-mutually exclusive mechanisms: downregulation of TGF-β1 receptor (TGF-βR) expression, and inhibition of flk-1 expression (Anders et al., 1997; Mandriota et al., 1996; Minami et al., 2001 ). Our observation is also consistent with a recent report that induction of endothelial cell death is followed by increased proliferation and resistance to apoptosis (Sakao et al., 2005) . A variety of tumors contain high levels of both TGF-β1 and VEGF, which do not result in massive endothelial cell apoptosis. Our finding of the transient nature of TGF-β1-induced apoptosis, and the known effect of TGF-β1 on TGF-βR and flk-1 expression can explain the apparent lack of endothelial cell apoptosis in these tumors. , 2007) . In addition, to the best of our knowledge, our previous (Ferrari et al., 2006) and present work is the first that tested the effect of siRNA-mediated downregulation of flk-1 expression on endothelial cell apoptosis. The specificity of the effect of the flk-1 siRNA we used is shown by its lack of downregulation of flt-1 expression. Our finding that inhibition of VEGF -flk-1 signaling does not induce rapid endothelial cell apoptosis is also supported by our analysis of endothelial cell apoptosis in the CAM. In these experiments TGF-β1 induced endothelial cell apoptosis as rapidly (6 h) as in vitro. Inhibition of VEGF by neutralizing antibody did not increase endothelial cell apoptosis in the presence of TGF-β1; on the contrary, it blocked the apoptotic effect of TGF-β1. Based on our data we cannot exclude that inhibition of VEGF or flk-1 expression for a longer time would result in apoptosis in the absence of TGF-β1.
However, our results show that the rapid apoptotic effect of TGF-β1 on endothelial cells requires VEGF signaling and is necessary for the progression of the angiogenic process.
Thus, VEGF-flk-1 signaling not only provides endothelial cells with pro-survival and proliferative/migratory stimuli required for vessel formation but also mediates the initial apoptotic effect necessary for TGF-β1 induction of angiogenesis.
Inhibition of VEGF signaling -which blocks TGF-β1 induction of apoptosis -blocked in vitro angiogenesis with no apparent morphological changes in the endothelial cell monolayer. Conversely, inhibition of FGF-2 -which induces apoptosisresulted in few scattered and disrupted capillary-like structures. Thus, both inhibition of and excess apoptosis block angiogenesis, indicating that an optimal level of apoptosis is required for vessel formation.
Our experiments on the generation of vascular structures in embryoid bodies, a process that involves both vasculogenesis and angiogenesis, provide a genetic demonstration of the role of VEGF signaling in TGF-β1 induction of angiogenesis.
Consistent with previous observations (Feraud et al., 2001; Gualandris et al., 2000b) , both VEGF and TGF-β1 increased endothelial cell differentiation and formation of a vascular network in embryoid bodies. However, we found that TGF-β1 has no such effect on embryoid bodies genetically deficient in VEGF.
A previous report has shown that TGF-β1 increases endothelial cell differentiation in a VEGF-independent manner and inhibits endothelial tube formation in embryoid bodies (Mallet et al., 2006) . Two reasons can explain this discrepancy with our results. The independence of TGF-β1 action from VEGF was shown by using a neutralizing antibody added a day 0 of differentiation; in contrast, we used cells genetically deficient in VEGF or VEGF receptors. In addition, the authors used PECAM as a marker of endothelial cell differentiation, whereas we used ICAM-2. These endothelial cell markers have different expression patterns during embryoid body differentiation. In differentiating embryoid bodies PECAM+ cells can be found that are not organized into vessels, suggesting that PECAM+ cells are endothelial cell precursors;
conversely, ICAM-2+ cells are confined to patent vasculature (Bautch et al., 2000) . 
Our findings that TGF-β1 induces apoptosis and angiogenesis in vitro and
in vivo through the autocrine or paracrine activation of flk-1 by VEGF indicate a potential pharmacological approach to anti-angiogenesis therapy. High levels of VEGF, flk-1 and TGF-β1 are present in many tumors. Crosstalk between the signaling pathways activated by these growth factors controls endothelial cell apoptosis (Ferrari et al., 2006) and angiogenesis. Understanding the mechanism(s) that modulate this crosstalk can permit the development of novel pharmacological tools to convert VEGF, a potent angiogenesis inducer and survival factor, into an inducer of uncontrolled endothelial cell apoptosis, and therefore into a potent anti-angiogenesis factor. 
MATERIALS AND METHODS
Materials
Cells and Media. Bovine capillary endothelial cells (BCE) and human umbilical vein
endothelial cells (HUVE; Cascade Biologics, Portland, OR) were grown as described (Ferrari et al., 2006) .
Embryoid bodies. Wild-type mouse embryonic stem (ES) cells and embryonic mouse
fibroblast cells (EMFI) established as described (Su et al., 1999) were provided to us by Dr. A. Joyner (Memorial Sloan-Kettering Institute, New York). ES cells genetically deficient in either VEGF or VEGFR-1 or -2 were provided to us by Drs. Andras Nagy (Samuel Lunenfeld Research Institute, Toronto, Canada) (Carmeliet et al., 1996) , Janet Rossant (University of Toronto, Ontario, Canada) (Fong et al., 1995) and Guo-Hua Fong (University of Connecticut) (Fong et al., 1995) , respectively. ES cell culture and differentiation into embryoid bodies were performed as described (Gualandris et al., 2000a) .
Western blotting.
Western blotting was performed as described (Ferrari et al., 2006) . C, after which medium supplemented with 10% serum was added (Ferrari et al., 2006) .
The cells were used 48 h after transfection. In vivo apoptosis and angiogenesis assays on the chick chorioallantoic membrane (CAM). Angiogenesis assays were performed as described (Brooks et al., 1999) using filter disks soaked with hydroxycortisone acetate (Sigma; 2.5 mg/ml in 95% ethanol). To characterize endothelial cell apoptosis CAMs were separated from the paper disks after 6 h incubation at 38 o C and snap frozen in OTC. Four-micrometer sections were cut and stained with antibodies to CD31 and with the FragEL DNA Fragmentation Kit for TUNEL analysis (Calbiochem; San Diego, CA), and counterstained with DAPI. The 20 sections were observed under a confocal microscope, and TUNEL-positive cells were counted in ten 100X fields. Five CAMs per sample were used. To characterize angiogenesis CAMs were incubated at 38 o C for 72 h, and the number of branching blood vessels within the area of the filter disks was counted by stereomicroscopy as described (Brooks et al., 1999) . Eight CAMs per condition were used. The CAMs were photographed with a digital camera connected to the microscope.
Reverse transcription-polymerase chain reaction (RT-PCR
Statistical Analysis. t-tests on the equality of means were performed using Stata 8.
21
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. (1996) ethanol) plus or minus the indicated reagents were applied on 10-day old CAMs as described (Brooks et al., 1999) . After 6 h incubation at 38 o C the CAMs were separated from the paper disks, snap frozen in OTC and 4 μm sections were cut. The histograms represent mean ± SE of the number of vessels/CAM determined in three independent experiments (8 CAMs/sample/experiment). *: p < 0.05 (sample vs. control).
